Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

FDA Clears Pfizer’s Xeljanz for Inflammatory Bowel Disease

Reuters Staff  |  

(Reuters)—The U.S. Food and Drug Administration said on Wednesday that it had approved Pfizer Inc’s drug, Xeljanz, to treat adults with moderate-to-severe active ulcerative colitis.

The effectiveness of Xeljanz (tofacitinib) in treating ulcerative colitis was shown in three controlled clinical trials, including two trials that showed the drug caused disease remission in about 17-18 percent of the patients.

ADVERTISEMENT
SCROLL TO CONTINUE

The FDA’s announcement is here: http://bit.ly/2kA4FJN.

The drug is already approved by the FDA to treat rheumatoid arthritis and psoriatic arthritis.

ADVERTISEMENT
SCROLL TO CONTINUE

Related Articles

    FDA Declines to Expand Approval of Pfizer Arthritis Drug Xeljanz

    (Reuters)—U.S. health regulators declined to approve Pfizer Inc’s oral rheumatoid arthritis drug Xeljanz (tofacitinib) to treat moderate to severe cases of plaque psoriasis, the drugmaker said on Wednesday. Pfizer said it received a complete response letter from the Food and Drug Administration. Such letters typically outline concerns and conditions that must be addressed in order…

    Patients Don’t Realize Smoking Worsens Inflammatory Bowel Disease

    (Reuters Health)—Doctors know smoking can increase the risk for certain common inflammatory bowel diseases (IBD), but many patients haven’t gotten the message, a new study suggests. Out of 239 patients with two common types of IBD (Crohn’s disease and ulcerative colitis) only half were aware of the smoking risks associated with these conditions. ad goes…